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The efficacy and safety of intravenous propafenone was
studied in leipatients with WoltT·Parkinson-White syn-
drome and in 2 patients with a concealed accessory path-
way. During electrophysiologic study, the etTect of pro-
pafenoneon the effective refractory period ofthe accessory
pathway was determined, as well as its etTect during
orthodromic atrioventricular (AV) reentrant tachycar-
dia and atrial fibrillation. Prepafenone caused significant
increases in the accessory pathway refractory period,
both in the anterograde direction (290 ± 19 versus 474
± 50 ms, p < 0.05) and in the retrograde direction (238
± 15 versus 408 ± 44 ms, p < 0.05). Complete anter-
ograde accessory pathway conduction block occurred in
four patients.
Sustained AV reentrant tachycardia was inducible in
11 patients before administration of propafenone. Drug
infusion during AV reentrant tachycardia promptly ter-
The principal electrophysiologic effect of propafenone on
cardiac cells is blockade of the fast inward sodium current
during phase 0 of the action potential. The drug has little
effect on the time course of repolarization of cardiac cells
and, therefore, has been classified as a type lC agent (1-3).
Propafenone also has modest beta-adrenergic blocking ac-
tivity as well as weak calcium channel blocking activity
(4-7). However , the contribution of these effects to its anti-
arrhythmic action is uncertain. In humans , acute intravenous
administration of propafenone slows conduction and pro-
longs refractoriness in most regions of the heart (8,9) . These
electrophysiologic effects have been cited as the mecha-
nisms by which the drug suppresses both supraventricular
From the Clinical Electrophysiology Laboratory of the Brigham and
Women 's Hospital and the Department of Medicine , Harvard Medical
School , Boston , Massachusetts .
Manuscript received June 23, 1986; revised manuscript received No-
vember 19, 1986, accepted December 4, 1986.
Address for reprints: Peter L. Friedman , MD, Cardiovascular Division ,
Brigham and Women's Hospital, 75 Francis Street , Boston, Massachusetts
02115 .
©J987 by the American College of Cardiology
minated arrhythmia in 10of these 11 patients and caused
slowing of AV reentrant tachycardia in the remaining
patient. Before propafenone, sustained atrial fibrillation
was inducible in six patients and nonsustained atrial
fibrillation in four patients. After propafenone, no pa-
tient had inducible sustained atrial fibrillation. Fur-
thermore, propafenone caused a marked decrease in peak
ventricular rate during atrial fibrillation.
Eight patients have been treated with oral propafen-
one and followed up for 12 ± 2 months. All have re-
mained virtually free of recurrent arrhythmia and none
has developed significant side etTects. Propafenone is a
very promising agent for emergency intravenous therapy
as well as long-term oral therapy in patients with WoltT-
Parkinson-White syndrome.
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and ventricular arrhythmias in patients during long-term oral
therapy (9-15).
Using a randomized, double-blind, placebo-controlled,
conditional crossover experimental design, the present study
assessed the acute electrophysiologic effects of intravenous
propafenone in patients with Wolff-Parkinson-White syn-
drome and a history of syncope or recurrent supraventricular
arrhythmia unresponsive to conventional therapy . Propa-
fenone' s effects on the accessory pathway, orthodromic
atrioventricular (AV) reentrant tachycardia incorporating the
bypass tract and atrial fibrillation are reported . These results
are also correlated with efficacy of long-term oral propa-
fenone in those patients with Wolff-Parkinson-White syn-
drome at highest risk of sudden death because of rapid
ventricular rates during atrial fibrillation or in those with
disabling orthodromic AV reentrant tachycardia.
Methods
Study patients. Twelve consecutive patients (seven men
and five women, aged 18 to 59 years) with a manifest or
concealed accessory atrioventricular (AV) pathway, and with
0735-1097/87/$3.50
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a history of syncope or recurrent supraventricular arrhyth-
mia, or both, underwent programmed electrical cardiac
stimulation. All 12 patients had undergone previous unsuc-
cessful treatment with conventional agents including type I
antiarrhythmic agents, beta-adrenergic blockers and calcium
channel blockers. Ten of the 12 patients had typical Wolff-
Parkinson-White syndrome with delta waves during sinus
rhythm and evidence of ventricular pre-excitation during
electrophysiologic study. In two patients a concealed ac-
cessory pathway was suspected because of findings in the
surface electrocardiogram (ECG) during supraventricular
tachycardia and was subsequently confirmed by intracardiac
recordings; both concealed accessory pathways were left-
sided. Among the 10 patients with Wolff-Parkinson-White
syndrome the accessory pathway was left lateral in 4, left
paraseptal in 5 and right-sided in 1.
Electrophysiologic studies. These studies were per-
formed with patients in the sedated, postabsorptive state
after written informed consent was obtained. Under fluo-
roscopy, three to six bipolar or quadripolar electrode cath-
eters were positioned in the right atrium, right ventricular
apex and coronary sinus or left atrium. Three electrocar-
diographic (ECG) surface leads (I, II and VI) and four
intracardiac bipolar electrograms were recorded simulta-
neously on a direct-recording ink-jet recorder (Mingograph,
Siemens-Elema). High rate pacing and programmed stim-
ulation were performed using a programmable stimulator
(WPI Instruments).
The stimulation protocol included the determination at
two or more cycle lengths (chosen from 600, 500 or 400
ms) of atrial effective and functional refractory periods,
ventricular effective refractory period, accessory pathway
anterograde and retrograde effective refractory periods and
patterns of AV and ventriculoatrial (VA) conduction during
sinus rhythm, right ventricular pacing and induced supra-
ventricular arrhythmia. When the exact value of the acces-
sory pathway effective refractory period could not be de-
termined at a particularpaced cycle length, because conduction
over that structure occurred down to the functional refractory
period of the atrium (during anterograde refractory period
determination) or of the right ventricle (during retrograde
measurements), the value was approximated as being equal
to or less than that of these functional refractory periods.
Similarly, when complete block of conduction over the ac-
cessory pathway was noted after drug administration, ac-
cessory pathway refractory periods were approximated as
being equal to or greater than the basic paced cycle length.
Study design. All patients were admitted to the hospital
24 hours before electrophysiologic testing. Before study,
all patients taking cardiac glycosides, beta-adrenergic block-
ers, calcium channel blockers or antiarrhythmic agents
underwent a drug elimination period equivalent to five half-
lives. One patient (case 2) was taking amiodarone, 200 mg
daily, at the time of entry into the study and was continued
on that medication. Patients with congestive heart failure,
severe renal or hepatic disease, electrolyte abnormalities,
significant sinus node or conduction system disease or recent
myocardial infarction were excluded from participation.
A double-blind, randomized, conditional crossover ex-
perimental design was utilized to evaluate the comparative
short-term efficacy and safety of intravenous propafenone
versus placebo in these 12 patients. After baseline electro-
physiologic data were obtained, sustained supraventricular
tachycardia was induced using intracardiac programmed
electrical stimulation. The electrophysiologic characteristics
of the tachycardia were noted, after which drug A (that is,
placebo or 2 mg/kg body weight of propafenone) was ad-
ministered intravenously over 10 minutes. If conversion to
sinus rhythm occurred during the 10 minute infusion, repeat
electrophysiologic data were obtained and the study was
then terminated. However, if conversion to sinus rhythm
did not appear promptly, the arrhythmia was terminated
using programmed stimulation, after which repeat electro-
physiologic data were obtained. Supraventricular tachycar-
dia was then reinitiated by programmed electrical stimula-
tion and the patient was crossed over to the opposite
medication, drug B (that is, placebo or 2 mg/kg of propa-
fenone). Thus, drug B was not given if tachycardia termi-
nated during the 10 minutes within which drug A was ad-
ministered. In those patients whose arrhythmia had not been
terminated during infusion of drug A and who went on to
receive drug B, the infusion was again administered over a
10 minute period. If supraventricular tachycardia failed to
terminate spontaneously within this period it was terminated
by programmed stimulation, after which refractory period
measurements were again determined.
Once the study had been completed in all 12 patients and
the results were revealed, it became clear that in no instance
did placebo ever cause termination of tachycardia. Thus,
refractory period determinations before and after propafen-
one were available from each patient and form the basis of
this report. Whether tachycardia terminated spontaneously
during drug infusion or required programmed stimulation
for termination, at least 2 to 5 minutes were allowed to
elapse before refractory period measurements were made,
so that these values during paced cycle lengths were not
appreciably affected by the rapid rate that had been present
during tachycardia.
After electrophysiologic study some patients were con-
tinued on long-term oral propafenone therapy. These pa-
tients were selected because they met all of the following
criteria: 1) failure to respond to conventional antiarrhythmic
therapy in the past; 2) favorable response to acute intra-
venous propafenone; and 3) increased risk of sudden death
due to an extremely short accessory pathway refractory pe-
riod or disrupted lifestyle due to recurrent supraventricular
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Figure 1. Effect of propafenone (2 mg/kg intravenously) on the
anterograde effective refractory period (ERP) of the accessory
pathway in IO patients. Values for each patient before and after
the drug are plotted on the ordinate together with arrows indi-
catingthedirection of changeinducedby thedrug. The anterograde
effectiverefractory periodof theaccessory pathwayincreased after
administration of the drug by > 150 ms in six patients, with total
anterograde block of the accessory pathway occurring in four of
them (open circles). The effect of propafenone on the accessory
pathway anterograde effective refractory period was independent
of the control value. Asterisk indicates concealed accessory path-
way.
tion in all 12 patients. Before propafenone, it ranged from
180 to 390 ms and did not change after placebo. After
propafenone (2 mg/kg intravenously) infusion, 11 of the 12
patients had an increase in the retrograde effective refractory
period and 4 developed complete retrograde block (Fig. 2).
No patient showed a decrease in the retrograde effective
refractory period after the drug, although the interval re-
mained unchanged in one subject (Patient 6, Fig. 2). Over-
all, the retrograde effective refractory period of the acces-
sory pathway increased from 238 ± 15 to 408 ± 44 ms
(p < 0.05) after propafenone. In general, the effect of pro-
pafenone on the anterograde refractory period of the acces-
sory pathway did not bear any consistent relation to its effect
on that of the retrograde refractory period. Of the four sub-
jects in whom propafenone caused complete block of an-
terograde conduction over the accessory pathway (Patients
5, 7, 9 and 10, Fig. 1), only 2 (Patients 5 and 7; Fig. 2)
also had complete block of retrograde accessory pathway
conduction. Conversely, complete block ofretrograde con-
duction over the accessory pathway was noted in Patient 4
(Fig. 2), even though little effect on anterograde accessory
pathway refractory period was noted (Fig. 1).
I
•
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tachycardia, or both. Each patient taking oral propafenone
was followed up monthly for long-term efficacy and poten-
tial side effects.
Statistical analysis. Values are expressed as mean ±
SEM, and were evaluated for statistical significance by Stu-
dent's t test. Differences with probability (p) values of <0.05
were considered significant.
Results
Baseline arrhythmias. All 12 patients had baseline si-
nus rhythm. All patients had retrograde and 10 patients
anterograde conduction over the accessory pathway whereas
2 patients had a concealed left-sided accessory pathway.
Eleven patients had inducible sustained orthodromic AV
reentrant tachycardia incorporating an accessory pathway
as the retrograde limb of the tachycardia circuit. Ten had
inducible atrial fibrillation.
Atrial and ventricular refractory periods. The intra-
venous infusion of propafenone produced peak serum levels
of 4,355 ± 910 ng/m!. The effective refractory period of
the right atrium increased from 224 ± 7 to 252 ± 5 ms (p
< 0.05) after intravenous propafenone and was unchanged
after placebo (224 ± 7 versus 223 ± 9 ms, p = NS). The
functional refractory period of the right atrium lengthened
after intravenous propafenone from 273 ± 6 to 302 ± 4
ms (p < 0.05) and did not change after placebo (273 ± 6
versus 271 ± 9 ms, p = NS). The effective refractory
period of the right ventricle was slightly increased after
intravenous propafenone from 231 ± 4 to 247 ± 3 ms (p
< 0.05) but not with placebo (231 ± 4 to 232 ± 5 ms, p
= NS).
Anterograde conduction over the accessory pathway.
The anterograde effective refractory period of the 10 ac-
cessory pathways capable of anterograde conduction was
determined by stimulating from the atrial site closest to the
atrial end of the accessory pathway. Before initiation of
treatment, the anterograde effective refractory period of the
accessory pathway ranged from 210 to 440 ms, and in each
patient given placebo this value remained unchanged. After
propafenone (2 mg/kg intravenously), complete anterograde
block developed in the accessory pathway of 4 of these 10
patients (Fig. 1). In an additional three individuals the re-
fractory period of the accessory pathway was markedly pro-
longed by 170, 130 and 70 ms, respectively, whereas in
three others the refractory period increased by 30 ms. In no
patient did the anterograde effective refractory period of the
accessory pathway decrease or remain unchanged; overall,
it increased from 290 ± 19 to 474 ± 50 ms (p < 0.05)
after propafenone.
Retrograde conduction over the accessory pathway.
The retrograde effective refractory period of the accessory
pathway was determined before and after drug administra-
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10 minutes caused termination of AV reentrant tachycardia
in 10 of 11 individuals before the drug infusion was com-
plete and lengthening of the AV reentrant tachycardiacycle
length in the remaining individual. The mechanism of ter-
mination of AV reentranttachycardiawith propafenonewas
retrograde block in the accessorypathway in seven patients
and anterograde blockin the AV node in three. Termination
of AV reentrant tachycardia due to retrograde block in the
accessory pathwaywas observedin those patientswho dem-
onstrated the greatest drug-induced prolongation of retro-
gradeaccessory pathwayrefractory period. However, it was
also observed in several of the patients whose retrograde
accessory pathway refractory period prolonged only mod-
estly. In only2 of 11 patientscouldAV reentranttachycardia
be reinduced after propafenone, although at a slower rate.
Effect of propafenone during atrial fibrillation (Table
2). In 10of the 12patients, prematureatrial stimulior rapid
high right atrial stimulation, or both, induced atrial fibril-
lation. The minimal pre-excited RR interval during atrial
fibrillation ranged from 180 to 270 ms in eight individuals,
whereas two showed only sporadic pre-excited conduction
during atrial fibrillation. After propafenone (2 mg/kg intra-
venously), each patientdemonstrated an increasein the min-
imal pre-excited RR interval during atrial fibrillation and
three had completeblock of anterograde accessorypathway
conduction during atrial fibrillation. The minimal pre-ex-
cited RR interval during atrial fibrillation increased after
propafenone from 252 ± 30 to 327 ± 19 ms (p < 0.05).
Two of the four subjects who had complete block of an-
terograde accessory pathway conduction during refractory
period determinations (Patients 5 and 10, Fig. 1) also had
no anterograde conduction over the accessorypathway dur-
ing atrial fibrillation, whereas the remaining two (Patients
7 and 9) still demonstrated conduction over the accessory
pathway during atrial fibrillation. Conversely, anterograde
accessory pathway conduction during atrial fibrillation was
completely abolished in Patient6, even thoughonly a mod-
I % I I
...I
2 3 4 5 6 7 8 9 10 11 12
Patient
Effect of propafenone during sustained orthodromic
AV reentrant tachycardia incorporating the accessory
pathway (Table 1). In 11 patients prematureatrial or ven-
tricularstimuliprovokedsustainedAV reentranttachycardia
conducting anterograde over the AV node and retrograde
over the accessory pathway. According to the study design,
in a blindedfashion, seven patients receivedplacebobefore
the active drug. Placebo caused spontaneous termination of
AV reentrant tachycardia in none of these seven patients,
and AV reentrant tachycardia with the same characteristics
was reinducible in all patients after placebo administration.
In contrast, propafenone (2 mg/kg intravenously) givenover
Figure2. Effect of propafenone (2 mg/kg intravenously) on the
accessory pathway retrograde effective refractory period (ERP) in
all 12 patients. Values before and after administration of the drug
are plotted on the ordinate with arrows indicating the direction
of change induced by the drug. Retrograde effective refractory
period oftheaccessory pathway increased in II of the 12 patients,
with complete block in the retrograde direction occurring in four
patients (open circles).
Table 1. Effect of Propafenone Versus Placebo During
Sustained Orthodromic AV Reentrant Tachycardia Incorporating
the Accessory Pathway in 11 Patients
Table 2. Effect of Propafenone During Atrial Fibrillation
in 10Patients
Minimal Pre-excited RR Interval (ms)
Results are expressed as number of patients. AV = atrioventricular.
Spontaneous termination
of tachycardia
Mechanism of
termination
Retrograde block in
accessory pathway
Anterograde block in
AV node
Reinducibility of
sustained tachycardia
Placebo
oof 7
7 of 7
Propafenone
10 of II
7 of 10
3 of 10
2 of 11
Patient After
No. Control Propafenone
3 240 290
4 230 310
5 270 Absent
6 200 Absent
7 Sporadic Sporadic
8 Sporadic Sporadic
9 180 380
10 180 Absent
II 270 300
12 190 280
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est increase in anterograde accessory pathway refractory
period was demonstrated (Fig. 1).
Of the 10 patients who had atrial fibrillation induced
during placebo, 6 had sustained atrial fibrillation lasting >30
minutes or producing hypotension and requiring direct cur-
rent cardioversion. After intravenous propafenone (2 mglkg),
no patient had inducible sustained atrial fibrillation, but
nonsustained atrial fibrillation occurred in all.
Side effects. Because the dose of propafenone used dur-
ing intravenous infusion in the present study was a relatively
large one, particular attention was paid to the development
of untoward side effects. Nine of the 12 individuals treated
with intravenous propafenone reported no subjective ill ef-
fects, and no significant changes in hemodynamic state were
observed. Two patients developed nausea and vomiting,
accompanied by sinus bradycardia and mild hypotension.
One of these individuals responded to saline solution in-
fusion with prompt resolution of nausea and a return to
baseline hemodynamic state. The second patient received a
brief infusion of dopamine along with saline solution and
recovered completely within 30 minutes. Nausea and vom-
iting were observed briefly in one patient, without accom-
panying bradycardia or hypotension.
Long-term efficacy of propafenone. The effect of long-
term administration of oral propafenone was assessed in 8
of the 12 patients. In three of the remaining four patients,
long-term therapy was not instituted because of a long an-
terograde accessory pathway refractory period before drug
administration. One patient did not have a substantial ben-
eficial response to propafenone during acute drug testing
and required surgical ablation of the accessory pathway.
The duration of follow-up was 12 ± 2 months. The daily
dosage of propafenone was 694 ± 91 mg (range 450 to
1,200 mg daily). Six of eight patients did not report any
episodes of symptomatic tachycardia during the follow-up
period. One patient noted a single episode of sustained AV
reentrant tachycardia that responded to a higher dose of
propafenone. One patient (Case 6), despite a favorable acute
response to propafenone, continued to have symptomatic
supraventricular arrhythmias necessitating surgical ablation
of the accessory pathway 2 weeks after starting the oral
agent. No patient reported worsening of arrhythmia and no
patient died during the 12 ± 2 month follow-up. Side effects
included a common metallic taste and rare mild gastroin-
testinal upset, but no patient required discontinuation of
propafenone for side effects. There were no laboratory ab-
normalities of hematologic, renal or hepatic function.
Discussion
EIectrophysioIogic effects of propafenone. Extensive
animal work has shown that propafenone decreases the max-
imal upstroke velocity during phase 0 of the action potential
and shortens action potential duration in atrial and ventric-
ular muscle, and thus is a class 1C antiarrhythmic agent
(1-3). Although propafenone's major action is blockade of
the fast sodium channel, it also produces modest inhibition
of bronchial and cardiac beta-receptors, and minimal block-
ade of the calcium channel (4-7). Human studies (8,9) have
shown that propafenone prolongs atrial and ventricular re-
fractory periods and slows conduction velocity in all regions
of the heart. Furthermore, propafenone has been shown to
be effective for control of supraventricular and ventricular
arrhythmias (9-15). Electrophysiologic evaluations of pro-
pafenone in patients with Wolff-Parkinson-White syndrome
and life-threatening arrhythmias are limited and uncon-
trolled (16-20). In light of this, using a randomized, double-
blind, placebo-controlled, conditional crossover design, we
evaluated propafenone's effect in patients with Wolff-Par-
kinson-White syndrome and syncope or symptomatic supra-
ventricular arrhythmias, or both, in whom conventional anti-
arrhythmic agents (type I, beta-adrenergic blockers and
calcium blockers) had failed.
The results of acute electrophysiologic testing in our pa-
tients with Wolff-Parkinson-White syndrome revealed that
propafenone uniformly increased refractoriness of the atrium,
ventricle and accessory pathway in both the anterograde and
retrograde directions. Complete anterograde or retrograde
block in the accessory pathway occurred in half the patients,
the increment in refractory period being independent of the
control refractory period. In contrast to previous observa-
tions with procainamide, quinidine, ajmaline and amioda-
rone (21), our data are consistent with other data (14,17,22)
showing that the actions of propafenone are independent of
the initial duration of the accessory pathway refractory pe-
riod. These findings suggest that propafenone might benefit
patients with Wolff-Parkinson-White syndrome character-
ized by an accessory pathway with a short refractory period,
who are thereby at highest risk for ventricular fibrillation
should atrial fibrillation supervene.
Efficacy of AV reentrant tachycardia. In our patients
with induced sustained orthodromic AV reentrant tachy-
cardia incorporating an accessory pathway, propafenone (2
mg/kg intravenously) quickly terminated the tachycardia in
10 individuals (91%) and prevented its reinduction in 9
(82%). These favorable results with intravenous propafen-
one may in part be related to the high dose utilized. We
administered a dose that produced transient serum propa-
fenone levels two to eight times the recommended thera-
peutic level of 500 to 2,000 ng/ml. Although rapid redis-
tribution of drug after completion of the infusion undoubtedly
caused plasma propafenone levels to fall promptly into the
usual therapeutic range, the very high plasma concentrations
achieved transiently in our study undoubtedly contributed
to the efficacy of the drug in terminating established AV
reentrant tachycardia and in preventing its reinduction. Pre-
vious studies (16-20) using a range of propafenone dosages
(1, 1.5 and 2 mg/kg intravenously) demonstrated that pro-
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pafenone prevents reinduction of AV reentrant tachycardia
in 0 to 50% of patients with Wolff-Parkinson-White syn-
drome. These studies did not, however, evaluate mecha-
nisms of termination of AV reentrant tachycardia or cor-
relate drug effect with serum drug levels.
Efficacy during atrial fibrillation. A particularly note-
worthy finding of the present study was the salutary effect
propafenone exerted during atrial fibrillation. Patients with
Wolff-Parkinson- White syndrome whose accessory path-
way has a very short anterograde refractory period are at
particular risk for developing ventricular fibrillation should
atrial fibrillation supervene (23,24). The ideal antiarrhyth-
mic drug for such patients would have the following attri-
butes: 1) availability for acute intravenous administration
as well as long-term oral therapy, 2) ability to cause marked
and reliable prolongation of the anterograde accessory path-
way refractory period, and 3) ability to terminate atrial fi-
brillation promptly and to prevent subsequent episodes or,
at least, to reduce their duration. No currently available
antiarrhythmic agent has all of these ideal attributes. Most
available drugs cause very little increase in the anterograde
accessory pathway refractory period when the initial re-
fractory period is very short, thereby providing little pro-
tection from excessive ventricular rates during atrial fibril-
lation (21). Indeed, an increase rather than a decrease in
ventricular rate during atrial fibrillation has been reported
after intravenous administration of several agents (25,26).
Propafenone seems to stand in contrast to other antiar-
rhythmic drugs as evidenced by the results of the present
study. In all of our patients with Wolff-Parkinson-White
syndrome, administration of propafenone caused a prompt
and striking decline in the minimal pre-excited RR interval
during atrial fibrillation, a reflection of the drug's ability to
increase the anterograde refractory period of accessory path-
ways irrespective of the initial refractory period. Indeed, in
three of our patients, intravenous propafenone completely
abolished anterograde conduction over the accessory path-
way during atrial fibrillation. The ability of propafenone to
increase the accessory pathway anterograde refractory pe-
riod independent of its initial value may not be characteristic
of all type Ie drugs. This effect was not seen in a previous
study with flecainide (27), although it has been described
for lorcainide (28). Flecainide also appears to be less ef-
fective than propafenone in preventing induction of AV
reentrant tachycardia during programmed stimulation (29).
Importantly, none of the patients in the present study dem-
onstrated an increase in ventricular rate after drug admin-
istration. Of great interest, after propafenone administration
the induced episodes of atrial fibrillation in 10 patients were
always nonsustained and of very brief duration. In six of
those patients, atrial fibrillation had been sustained before
drug administration and had required cardioversion for ter-
mination. In four patients, atrial fibrillation induced during
the control period had been nonsustained. After propafenone
administration in these four patients, the duration of induced
nonsustained atrial fibrillation was abbreviated. These an-
tifibrillatory actions of propafenone in patients with Wolff-
Parkinson-White syndrome have not been described pre-
viously. Our results suggest that the drug may be very useful
in emergency situations to slow the ventricular rate and
terminate atrial fibrillation in such patients, avoiding the
necessity for electrical cardioversion.
Tberapeutic implications. Our results suggest that pro-
pafenone is an effective agent, not only for intravenous
therapy of AV reentrant tachycardia or atrial fibrillation in
patients with Wolff-Parkinson-White syndrome, but also for
long-term oral therapy in such patients troubled by recurrent
arrhythmias. Those patients in our study who demonstrated
a beneficial response to acute intravenous administration of
propafenone were subsequently given long-term oral ther-
apy. With only one exception, all of these patients reported
virtual abolition of recurrent arrhythmias during the follow-
up period. Bothersome side effects during long-term oral
propafenone therapy were unusual and minor and in no
patient necessitated discontinuation of the drug. Thus, pro-
pafenone seems to be a safe, well tolerated and effective
drug for the short- and long-term therapy of patients with
Wolff-Parkinson-White syndrome and recurrent arrhythmia.
This drug, even in patients who are at increased risk for
ventricular fibrillation due to rapid conduction over the ac-
cessory pathway during atrial fibrillation, may offer an at-
tractive alternative to surgical therapy.
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